

17 May 2018

### June 2018 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **June 2018** Update to the Pharmaceutical Schedule. Please notify PHARMAC ([enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)) if you want to change or remove your contact details.

#### New listings

- Afibercept (Eylea) inj 40 mg per ml, 0.1 ml vial – Special Authority – Retail pharmacy (p'code 2441195)
- Aminoacid formula without phenylalanine (PKU Lophlex Powder) powder (unflavoured) 27.8 g sachet – Special Authority – Hospital pharmacy [HP3] (p'code 2541092)
- Amino acid formula (Neocate Advance) powder (unflavoured) (p'code 2212285) and (vanilla) (p'code 2400472), 400 g OP – Special Authority – Hospital pharmacy [HP3]
- Aripiprazole (Aripiprazole Sandoz) tab 5 mg (p'code 2544520), 10 mg (p'code 2544539), 15 mg (p'code 2544547), 20 mg (p'code 2544555) and 30 mg (p'code 2544563) – Safety medicine; prescriber may determine dispensing frequency
- Calcium folinate (Calcium Folate Sandoz) inj 10 mg per ml, 100 ml vial – PCT only – Specialist (p'code 2539225)
- Dantrolene (Dantrium S29) cap 25 mg – S29 and wastage claimable (p'code 2512580)
- Ezetimibe (Ezetimibe Sandoz) tab 10 mg – Special Authority – Retail pharmacy (p'code 2545861)
- Gabapentin (Apo-Gabapentin) cap 100 mg (p'code 2540754), 300 mg (p'code 2540762) and 400 mg (p'code 2540770) – not subsidised in combination with subsidised pregabalin
- Imiquimod (Perrigo) crm 5%, 250 mg sachet (p'code 2543907)
- Mercaptopurine (Allmercap) oral suspension 20 mg per ml, 100 ml OP – Special Authority – Retail pharmacy-Specialist (p'code 2545551)
- Tenofovir disoproxil (Tenofovir Disoproxil Teva) tab 245 mg (300.6 mg as a succinate) – Tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals (p'code 2544121)
- Travoprost (Travatan) eye drops 0.004%, 2.5 ml OP (p'code 2144581)
- Ziprasidone (Zeldox) cap 20 mg (p'code 2260239) – Safety medicine; prescriber may determine dispensing frequency

**Changes to restrictions, chemical names and presentations**

- Adalimumab inj 20 mg per 0.4 ml and inj 40 mg per 0.8 ml prefilled syringes (Humira) and inj 40 mg per 0.8 ml prefilled pen (HumiraPen) – amended Special Authority criteria
- Aripiprazole (Abilify) tablet 5 mg and tab 10 mg, 15 mg, 20 mg and 30 mg – amended presentation description (tablet 5 mg) and Special Authority moved to brand level
- Entecavir (Baraclude) tab 0.5 mg – addition of STAT (all-at-once) dispensing and Special Authority removed
- Etanercept (Enbrel) inj 25 mg, and inj 50 mg autoinjector and 50 mg prefilled syringe – amended Special Authority criteria
- Ezetimibe (Ezetimibe Sandoz) tab 10 mg – addition of STAT (all-at-once) dispensing
- Gabapentin (Arrow-Gabapentin, Neurontin and Nupentin) cap 100 mg, 300 mg and 400 mg – Special Authority moved to brand level
- Naloxone hydrochloride (DBL Naloxone Hydrochloride) inj 400 mcg per ml, 1 ml ampoule – amended brand name
- Pharmaceuticals with standardised formula for compounding in Ora products – sulfasalazine 100 mg/ml – amended chemical name
- Sulfasalazine tab 500 mg (Salazopyrin) and tab EC 500 mg (Salazopyrin EN) – amended chemical name
- Tenofovir disoproxil tab 245 mg (300 mg as a fumarate) (Viread) and tab 245 mg (300.6 mg as a succinate) (Tenofovir Disoproxil Teva) – addition of STAT (all-at-once) dispensing, amended presentation description and removal of endorsement and Special Authority

**Increased subsidy**

| Chemical             | Presentation   | Fully subsidised brands                           |
|----------------------|--|---|
| Heparin sodium       | Inj 1,000 iu per ml, 35 ml vial<br>Inj 1,000 iu per ml, 5 ml<br>Inj 5,000 iu per ml, 5 ml<br>Inj 5,000 iu per ml, 1 ml<br>Inj 25,000 iu per ml, 0.2 ml | Hospira<br>Pfizer<br>Pfizer<br>Hospira<br>Hospira |
| Heparinised saline   | Inj 10 iu per ml, 5 ml   | Pfizer  |
| Paracetamol          | Oral liq 250 mg per 5 ml   | Paracare Double Strength                          |
| Salbutamol           | Oral liq 400 mcg per ml  | Ventolin  |
| Sodium nitroprusside | Test strips, 50 strip OP   | Ketostix  |
| Sulfadiazine sodium  | Tab 500 mg   | Wockhardt   |
| Voriconazole         | Powder for oral suspension<br>40 mg per ml   | Vfend   |

**Decreased subsidy**

| <b>Chemical</b>        | <b>Presentation</b>              | <b>Fully subsidised brands</b> | <b>Partially subsidised brands</b> |
|------------------------|----------------------------------|--------------------------------|------------------------------------|
| Ciprofloxacin          | Eye drops 0.3%, 5 ml OP          | Ciprofloxacin Teva*            | Ciloxan                            |
| Doxycycline            | Tab 50 mg                        |                                | Doxy-50                            |
| Lidocaine [lignocaine] | Gel 2%, 10 ml urethral syringe   | Cathejell                      |                                    |
| Naloxone hydrochloride | Inj 400 mcg per ml, 1 ml ampoule | DBL Naloxone Hydrochloride     |                                    |
| Riluzole               | Tab 50 mg                        | Rilutek                        |                                    |

\* no subsidy changes for these brands for 1 June 2018.